急性卒中患者血栓切除术后MR-DWI梗死进展:随机接受Nerinetide或安慰剂的REPERFUSE-NA1研究
REPERFUSE-NA1是ESCAPE-NA1随机对照试验的前瞻性多中心MRI亚研究,纳入67例急性大血管闭塞性卒中行血管内治疗的患者,序贯MRI评估梗死进展。Nerinetide组与安慰剂组早期梗死进展无显著差异;未接受阿替普酶的患者中,Nerinetide组白质和基底节区梗死增长率降低。
要点
- Nerinetide组与安慰剂组早期梗死进展无显著差异(5.92 mL vs 10.80 mL,p=0.30)。
- 未接受静脉阿替普酶的患者中,Nerinetide组白质梗死增长率降低120%(SE 60%,p=0.03)。
- 未接受静脉阿替普酶的患者中,Nerinetide组基底节区梗死增长率降低340%(SE 140%,p=0.02)。
核心结论
- 急性大血管闭塞性卒中患者血管内治疗后早期梗死进展在灰质和白质均明显;Nerinetide对总早期梗死进展无显著影响。
- 在未接受静脉阿替普酶的患者中,Nerinetide与白质和基底节区梗死进展百分比轻度降低相关。
研究设计与样本
- REPERFUSE-NA1为前瞻性多中心MRI亚研究,嵌套于随机对照试验ESCAPE-NA1(NCT02930018)。
- 纳入发病12小时内行血管内治疗的急性致残性大血管闭塞性卒中患者,随机接受静脉Nerinetide或安慰剂。
- 71例纳入患者中67例MRI质量合格;于血管内治疗后<5小时(第1天)和24小时(第2天)行序贯MRI。
- 主要结局为血管内治疗后早期总扩散加权MRI梗死进展,即第2天与第1天病灶体积差;次要结局为不同脑组织区域的梗死进展。
主要发现
- 血管内治疗后中位梗死体积:Nerinetide组12.98 mL(IQR 5.93-28.08),对照组10.80 mL(IQR 3.11-24.45),p=0.59。
- 中位早期继发梗死进展:Nerinetide组5.92 mL(IQR 1.09-21.30),安慰剂组10.80 mL(IQR 2.54-21.81),p=0.30。
- 未接受阿替普酶的患者中,校正混杂因素后,Nerinetide组较安慰剂组白质梗死增长率降低120%(SE 60%),p=0.03。
- 未接受阿替普酶的患者中,校正混杂因素后,Nerinetide组较安慰剂组基底节区梗死增长率降低340%(SE 140%),p=0.02。
- 静脉阿替普酶改变了Nerinetide对白质和基底节区区域特异性梗死进展的效应。
临床怎么用
- 作者认为,本研究突显了MR成像作为生物标志物评估神经保护剂在急性卒中治疗中效果的潜力。
局限性
- 本研究总体梗死体积相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The neuroprotectant nerinetide has shown promise in reducing infarct volumes in primate models of ischemia reperfusion. We hypothesized that early secondary infarct growth after endovascular therapy (EVT) (1) may be a suitable surrogate biomarker for testing neuroprotective compounds, (2) is feasible to assess in the acute setting using sequential MRI, and (3) can be modified by treatment with nerinetide. METHODS: REPERFUSE-NA1 was a prospective, multisite MRI substudy of the randomized controlled trial ESCAPE-NA1 (ClinicalTrials.gov NCT02930018) that involved patients with acute disabling large vessel occlusive stroke undergoing EVT within 12 hours of onset who were randomized to receive intravenous nerinetide or placebo. Patients enrolled in REPERFUSE-NA1 underwent sequential MRI <5 hours post-EVT (day 1) and at 24 hours (day 2). The primary outcome was total diffusion-weighted MRI infarct growth early after EVT, defined as the lesion volume difference between day 2 and day 1. The secondary outcome was region-specific infarct growth in different brain tissue compartments. Statistical analyses were performed using the Mann-Whitney U test and multiple linear regression. RESULTS: Sixty-seven of 71 patients included had MRI of sufficient quality. The median infarct volume post-EVT was 12.98 mL (IQR, 5.93-28.08) in the nerinetide group and 10.80 mL (IQR, 3.11-24.45) in the control group (p = 0.59). Patients receiving nerinetide showed a median early secondary infarct growth of 5.92 mL (IQR, 1.09-21.30) compared with 10.80 mL (interquartile range [IQR], 2.54-21.81) in patients with placebo (p = 0.30). Intravenous alteplase modified the effect of nerinetide on region-specific infarct growth in white matter and basal ganglia compartments. In patients with no alteplase, the infarct growth rate was reduced by 120% (standard error [SE], 60%) in the white matter (p = 0.03) and by 340% (SE, 140%) in the basal ganglia (p = 0.02) in the nerinetide group compared with placebo after adjusting for confounders. DISCUSSION: This study highlights the potential of using MR imaging as a biomarker to estimate the effect of a neuroprotective agent in acute stroke treatment. Patients with acute large vessel occlusive stroke exhibited appreciable early infarct growth both in the gray matter and the white matter after undergoing EVT. Acknowledging relatively small overall infarct volumes in this study, treatment with nerinetide was associated with slightly reduced percentage infarct growth in the white matter and basal ganglia compared with placebo in patients not receiving intravenous alteplase and had no effect on the total early secondary infarct growth. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT02930018. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with acute large vessel ischemic stroke undergoing EVT, nerinetide did not significantly decrease early post-EVT infarct growth compared with placebo.
引用
- Fladt J, Guo J, Specht JL, et al. Infarct Evolution on MR-DWI After Thrombectomy in Acute Stroke Patients Randomized to Nerinetide or Placebo: The REPERFUSE-NA1 Study. Neurology. 2023. PMID: 38165335. doi:10.1212/WNL.0000000000207976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。